z-logo
open-access-imgOpen Access
OPRM1 Gene Interaction with Sleep in Chronic Pain Patients Treated with Opioids
Author(s) -
Ana M. Peiró
Publication year - 2019
Publication title -
pain physician
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.31
H-Index - 99
eISSN - 2150-1149
pISSN - 1533-3159
DOI - 10.36076/ppj/2019.22.97
Subject(s) - medicine , chronic pain , sleep (system call) , opioid , anesthesia , physical therapy , receptor , computer science , operating system
Background: The experience of chronic non-cancer pain (CNCP) is one of the mostcommon reasons individuals seek medical attention. Patients with CNCP frequently experienceconcomitant sleep-related problems.Objectives: The aim was to evaluate sleep problems in opioid naïve CNCP patients, beforeand after opioid titration, analyzing the influence of OPRM1 gene variants.Study Design: A prospective, cohort, observational study.Setting: This study was performed at the Pain Unit of the Alicante University General Hospital.Methods: Pain and Medical Outcomes Study Sleep questionnaire (MOS-Sleep) were assessedat baseline and 3 months after opioid titration in 231 opioid naïve CNCP patients. Sleepdata was compared with a matched-control group (n = 64). Morphine equivalent daily doses,adverse events, and drugs prescribed for pain were also registered. OPRM1 polymorphismrs1799971 was analyzed by RT-PCR. Ethics Committee approved the study and results wereanalyzed by R software.Results: After 3 months of opioid titration, patients with CNCP (63 ± 14 years, 64% female,VAS 74 ± 17 mm) significantly decreased pain intensity, anxiety and depression, and increasedquality of life. Sleep problems were significantly more frequent in females (P = 0.002). Age,quality of life, anxiety, and depression all influenced sleep disturbances and problems indices,which were significantly different from the control group. Furthermore, the OPRM1 118-GG genotype was also associated with significantly lower sleep adequacy, and more sleepproblems.Limitations: Total number of subjects studied was relatively small and most patients were onother non-opioid centrally-acting medications.Conclusions: Opioids decreased CNCP severity, improving patients’ psychological areas, andquality of life. However, patients with OPRM1 118-GG genotype indicated an increase in sleepproblems and worsening sleep pattern while taking opioids.Key words: OPRM1, pharmacogenetics, MOS-Sleep, opioids, chronic noncancer pain, sleeprelated problems, sleep problem index SLP-6 and SLP-9

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom